SCHEMBL14712899

SCHEMBL14712899

CCN1C(=O)NC(=O)/C(=C\C=C\c2ccc(OC)cc2)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.56
APP P05067 6/20 0.56
SNCA P37840 6/20 0.56
MEN1 O00255 10/20 0.53
KMT2A Q03164 10/20 0.53
ALDH1A1 P00352 7/20 0.53
PKM P14618 5/20 0.53
MAPK1 P28482 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MITF O75030 2/20 0.53
LMNA P02545 3/20 0.50
L3MBTL1 Q9Y468 5/20 0.49
POLB P06746 4/20 0.49
USP2 O75604 2/20 0.49
NPSR1 Q6W5P4 3/20 0.47
NTSR1 P30989 2/20 0.47
MDM2 Q00987 1/20 0.47
BCL2A1 Q16548 1/20 0.47
APEX1 P27695 2/20 0.47
RECQL P46063 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14712900 0.86 MAPT (0.56) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14713066 0.85 MEN1 (0.64) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14712892 0.84 MAPT (0.72) MAPTAPPSNCAMEN1KMT2A
SCHEMBL14712877 0.82 MAPT (0.64) MAPTAPPSNCAMEN1KMT2A
SCHEMBL14713061 0.82 MAPT (0.58) MAPTAPPSNCAMEN1KMT2A
SCHEMBL16543009 0.82 MAPT (0.55) MAPTAPPSNCAMEN1KMT2A
SCHEMBL16543006 0.79 KMT2A (0.49) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL14712878 0.79 KMT2A (0.49) MAPTMEN1KMT2AALDH1A1PKM
SCHEMBL13317556 0.78 METAP1 (0.67) MAPTAPPSNCAMEN1KMT2A
SCHEMBL29705914 0.78 METAP1 (0.67) MAPTAPPSNCAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MAPT 2828/4885APP 4756/4885SNCA 4356/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 MAPT 3272/4885APP 4689/4885SNCA 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.